BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced promising preliminary relapse-free survival (RFS) data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset,…Read More
Elicio Therapeutics Presents Updated Preliminary Data Including Promising RelapseFree Survival Data from the Phase 1 Study of ELI002 at AACR Special Conference Pancreatic Cancer
